SRNE News and Press, Sorrento Therapeutics Inc. From 06/03/22

Sorrento's (NASDAQ:SRNE) subsidiary Scilex Holding on Friday has announced the pre-emptive repurchase of part of its senior secured notes. That allows the pain management company - Scilex - to repurchase $41.4M principal amount of notes on or before Sept. 30, 2022 and the holders of the notes...

STI-1558, an oral SARS-CoV-2 main protease inhibitor, is specifically designed as a standalone treatment and prevention of COVID-19 without the co-administration of ritonavir as a booster for CYP3A4 inhibition. STI-1558 is also a Cathepsin L inhibitor, which may block effective viral ...

SAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered by managed health care plans representing approximately 190 million of the over 300 milli...

Caris Life Sciences, Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling PR Newswire Collaboration will comprehensively profile DNA, RNA and proteins ...

A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker. The ASCO meeting presentation (ASCO Poster# 415) includes A166 dose expansion data administer...

Sorrento Therapeutics' (NASDAQ:SRNE)) majority-owned unit Scilex said the first patient was dosed in a phase 2 trial of SP-103 in patients with moderate to severe acute lower back pain (LBP). Scilex said its current marketed product, ZTlido (lidocaine topical system), has label claims re...

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80...

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of ...

Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MAB TM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories. COF has completed the pati...